A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions reduce its incidence and to assess the value of detailed instruction in increasing patient compliance and willingness to continue bimatoprost therapy, despite the occurrence of hyperemia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dr. Noecker

Pittsburgh, Pennsylvania, 15213, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

· Male or female > 18 years of age

No prior use of bimatoprost
Diagnosis of open-angle glaucoma or ocular hypertension
Ability to provide informed consent and likely to complete all study visits

Exclusion criteria

· Known contraindication to bimatoprost

Uncontrolled systemic disease
Active ocular disease other than glaucoma or ocular hypertension
Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
History of intraocular surgery within the last 3 months

Treatment and study plan

Bimatoprost

Drug

Sponsors and collaborators

Lead sponsor

Innovative Medical

Industry

Registry information

Important dates

First posted: Jul 4, 2006
Registry last updated: Jun 1, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed